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Abstract
PDAC (pancreatic ductal adenocarcinoma) is the fifth leading cause of cancer-related death. The causes of this
cancer remain unknown, but increasing evidence indicates a key role of the host immune response and cytokines in
human carcinogenesis. Intra-tumoral IL (interleukin)-22 levels have been shown to be elevated in PDAC patients.
However, little is known regarding the expression and clinical relevance of Th22 cells in human PDAC and,
furthermore, which TILs (tumour-infiltrating lymphocytes) are the main producers of IL-22 is unknown. In the present
study, we characterized the functional proprieties of the different subsets of IL-22-producing TILs and analysed their
relationship with the TNM staging system and patient survival. We have demonstrated for the first time that, in
PDAC patients, the T-cells co-producing IFN-γ (interferon γ ) and exerting perforin-mediated cytotoxicity are the major
intra-tumoral source of IL-22. In addition, isolated Th22 cells were able to induce apoptosis, which was antagonized
by IL-22. Finally, we observed that the IL-22-producing T-cells were significantly increased in tumour tissue and that
this increase was positively correlated with TNM staging of PDAC and poorer patient survival. These novel findings
support the dual role of the anti-tumour immune system and that IL-22-producing cells may participate in PDAC
pathogenesis. Therefore monitoring Th22 levels could be a good diagnostic parameter, and blocking IL-22 signalling
may represent a viable method for anti-PDAC therapies.
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INTRODUCTION
Pancreatic cancer is the fifth leading cause of cancer-related death
in the developed world, with more than 260000 annual deaths
worldwide [1] and with a dismal 5-year survival (5%). The leth-
ality of pancreatic cancer is due to its aggressive nature and its
tendency to remain asymptomatic until the tumour reaches an
advanced stage, limiting the likelihood of early diagnosis. At the
Abbreviations: BFA, brefeldin A; FoxP3, forkhead box P3; IFN-γ , interferon γ ; IL, interleukin; IL-10R2, IL-10 receptor 2; IL-22R, IL-22 receptor; mAb, monoclonal antibody; PBMC,
peripheral blood mononuclear cell; PD-1, programmed cell death 1; PDAC, pancreatic ductal adenocarcinoma; Tcc, T-cell clone(s); Th, T helper; TIL, tumour-infiltrating lymphocyte.
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time of initial presentation, most pancreatic cancers are locally
advanced or metastatic and need multimodal therapy [2], hence
the need to find factors that may facilitate earlier diagnosis and
improve prognosis of this neoplasia.
Pancreatic cancer originates in the ductal epithelium and
evolves from a pre-malignant lesion to fully invasive cancer.
The causes of pancreatic cancer remain unknown, although some
studies have shown that chronic inflammation is a common
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feature of actively growing pancreatic tumours [3]. Moreover, in-
creasing evidence has shown that the host immune response and
related inflammatory and immune mediators, such as cytokines,
participate in human carcinogenesis [4,5]. IL (interleukin)-22,
which belongs to the IL-10 cytokine family, is a T-cell-derived
cytokine that mediates epithelial immunity and mucosal tissue
repair [6]. IL-22 triggers intracellular signalling by binding to
a heterodimeric receptor complex that is composed of IL-22R1
(IL-22 receptor 1) and IL-10R2 (IL-10 receptor 2) [7]. How-
ever, the cellular responsiveness of IL-22 is mainly determined
by IL-22R1, which is selectively expressed on non-immune cells
[8], such as hepatocytes [9], keratinocytes [10], colonic epithelial
cells [11] and, particularly, pancreatic cells [12,13].
Principal sources of IL-22 include CD4+ Th (T helper) cells,
CD8+ CTLs (cytotoxic T-cells), γ δ T-cells and ILCs (innate
lymphoid cells), encompassing NK (natural killer) cells, LTi
(lymphoid tissue inducer)-like cells [14,15] and NKT (natural
killer T) cells [16]. Although several IL-22-producing CD4+
T-cells also produce other cytokines, such as IL-17 or IFN-γ
(interferon γ ) [17], some, only secrete IL-22 [18]. These CD4+
T-cells that exclusively secrete IL-22 are known as Th22 cells and
have been recently identified as the main producers of IL-22 in
the peripheral blood [19,20]. Th22 cells play important roles
in many inflammatory diseases, such as psoriasis [21], rheum-
atoid arthritis [22] and multiple sclerosis [23]. Moreover, IL-22
plays a pro-tumour role in cancers of the gastrointestinal tract.
Gastric tumours show increased infiltration of Th22, which cor-
relates with tumour stage and poor prognosis [24]. In addition,
compared with healthy controls, gastric cancer patients also have
higher circulating frequencies of IL-17- and IL-22-producing
T-cells, which are positively associated with cancer stage and
negatively with patient survival [25]. In colorectal cancer, levels
of both IL-17 and IL-22 are positively correlated with the tumour
stage [26], and serum IL-22 is elevated in chemoresistant patients
[27]. Moreover, IL-22 administration to human colorectal cancer
cell lines renders them chemoresistant [27]. In pancreatic cancer,
intra-tumoral IL-22 levels and frequency of Th22 cells are elev-
ated compared with the peripheral blood of patients and healthy
donors [28]. Similarly, expression of both IL-22 and IL-22R1 is
elevated in tissue sections of PDAC (pancreatic ductal adeno-
carcinoma) tissue [29]. However, little is known regarding the
expression and clinical relevance of Th22 in pancreatic cancer
and, furthermore, which TILs (tumour-infiltrating lymphocytes)
are the main producers of IL-22 is unknown. In the present study,
we have investigated the role of IL-22-producing T-cells during
PDACprogression. In detail, we have characterized the functional
proprieties of the different subsets of IL-22-producing CD4+ and
CD8+ Tcc (T-cell clones) generated from lymphocytes that in-
filtrate PDAC tissue, and we analysed their relationship with the
TNM staging system and patient survival.
MATERIALS AND METHODS
Patients
Tumours and corresponding adjacent tissues were obtained from
30 PDAC patients (14males and 16 females), whowere classified
according to the TNM classification for pancreatic tumours [30].
The mean age of the PDAC patients was 66 years (range 36–
92 years). The clinical characteristics of patients are summarized
in Table 1. All patients underwent surgical resection of the
primary lesion, but did not receive chemotherapy. Patients with
evidence of serious illness, immunosuppression, or autoimmune
or infectious diseases were excluded. The study was approved by
the local Ethical Committees (Azienda Ospedaliera Universit-
aria Careggi) and informed consent was obtained from all
patients.
Generation of Tcc from TILs of the neoplastic
pancreatic tissue
T-cell cultures were performed in RPMI 1640 culture medium
(SERO-Med) supplemented with 10% (v/v) HyCloneTM FBS
(Gibco Laboratories) and recombinant human IL-2 (EuroCetus).
Surgical specimens of PDAC tissue were cultured for 7 days in
RPMI 1640medium supplemented with IL-2 (50 units/ml), in or-
der to expand in vivo-activated TILs; in detail, tissue pieces from
each patient were obtained from two different sites, namely tu-
mour and surrounding healthy mucosa. Each specimen was then
disrupted, and single T-cell blasts were cloned under limiting dilu-
tion, as described previously [31]. Briefly, singleT-cell blastswere
seeded inmicrowells (0.3 cell/well) in the presence of 2×105 irra-
diated (9000 rad) PBMCs (peripheral blood mononuclear cells),
PHA (phytohaemagglutinin) (0.5%) and IL-2 (50 units/ml). At
weekly intervals, 2×105 irradiated PBMCs and IL-2 were ad-
ded to each micro-culture to maintain the expansion of grow-
ing clones. The Tcc were evaluated for their surface markers
and functional proprieties, namely cytokine profile, B-cell helper
activity and cell cytotoxicity.
Analysis of cell-surface markers and evaluation of
the cytokine profile of isolated Tcc
Fluorochrome-conjugated anti-CD3, -CD4, -CD8 and isotype-
matched control mAbs (monoclonal antibodies) were purchased
from BD Biosciences. We analysed surface marker (CD3, CD4
and CD8) expression in blasts of single Tcc by flow cytometry,
as described previously [31]. To evaluate the amount of secreted
cytokines, T-cell blasts of single Tcc were resuspended at a con-
centration of 106 cells/ml of medium and cultured for 36 h in
the presence of PMA (10 ng/ml) plus ionomycin (200 ng/ml).
Cell-free supernatants were collected and assayed in duplicate
for IFN-γ , IL-4, IL-17 and IL-22 content using commercial
ELISA kits (Bio-Source International). Supernatants presenting
cytokine levels that were 5 S.D. above the mean levels of control
supernatants derived from irradiated APCs (antigen-presenting
cells) alone were regarded as positive. On the basis of the eval-
uation of the cytokine profile and the CD4/CD8 expression, we
divided the clones into the following groups: Th22/Tc22 (only
IL-22), Th22Th1/Tc22Tc1 (IL-22+IFN-γ ), Th22Th2/Tc22Tc2
(IL22+IL-4), and Th22Th17/Tc22Tc17 (IL-22+IL-17).
B-cell helper activity
B-cells were prepared using the B-cell isolation kit II (Miltenyi
Biotec). A total of 2×105 B-cells were co-cultured with 105
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Table 1 Clinical parameters of patients with pancreatic cancer and Tcc isolated from cancer tissue
Code Age Sex TNM
Tumour
size
(cm) Metastasis
Overall
Survival
(months)
Tcc
obtained
IL-22-producing
Tcc (%)
01.PDAp 50 Male pT1, N1, Mx >3 − 11 84 12 (14)
02.PDAp 73 Male pT2, N1, Mx >3 − 13 26 4 (15)
03.PDAp 56 Male pT3, N0, Mx >3 ++ 8 6 4 (67)
04.PDAp 36 Male pT4, N1, M1 3 ++ 7 16 10 (63)
05.PDAp 74 Female pT3, N1, Mx >3 ++ 9 91 55 (60)
06.PDAp 61 Female pT4, N1, Mx >3 ++ 8 20 10 (50)
07.PDAp 63 Male pT1, N1, Mx >3 − 12 37 8 (22)
08.PDAp 74 Female pT4, N0, Mx >3 ++ 8 74 44 (59)
09.PDAp 54 Female pT2, N0, Mx >3 − 14 5 1 (20)
10.PDAp 92 Male pT3, N1, Mx 3 ++ 9 3 2 (67)
11.PDAp 57 Male pT2, N1, M1 3 + 10 22 8 (36)
12.PDAp 51 Female pT1, N1, Mx >3 − 11 13 2 (15)
13.PDAp 72 Female pT4, N1, Mx >3 ++ 8 22 15 (68)
14.PDAp 80 Female pT2, N1, M1 3 − 12 58 11 (19)
15.PDAp 58 Male pT1, N0, Mx 3 + 13 28 9 (32)
16.PDAp 55 Female pT1, N0, Mx 3 − 13 11 2 (18)
17.PDAp 70 Female pT2, N1, Mx >3 + 11 32 8 (25)
18.PDAp 62 Female pT3, N0, Mx >3 ++ 8 24 14 (58)
19.PDAp 42 Female pT4, N1, M1 >3 ++ 9 10 6 (60)
20.PDAp 58 Male pT1, N0, Mx >3 − 11 52 13 (25)
21.PDAp 74 Male pT4, N1, Mx >3 ++ 8 31 25 (81)
22.PDAp 79 Female pT4, N1, Mx 3 + 10 28 14 (50)
23.PDAp 83 Male pT4, N0, Mx >3 ++ 8 22 15 (68)
24.PDAp 62 Male pT1, N0, Mx >3 − 12 12 1 (8)
25.PDAp 85 Female pT1, N0, Mx 3 + 13 8 3 (38)
26.PDAp 76 Male pT2, N1, M1 3 + 12 18 8 (44)
27.PDAp 71 Male pT1, N1, Mx 3 + 11 7 2 (29)
28.PDAp 63 Female pT3, N1, Mx >3 ++ 8 11 7 (64)
29.PDAp 66 Female pT2, N1, M1 3 − 14 32 8 (25)
30.PDAp 72 Female pT4, N1, Mx 3 + 8 4 2 (50)
All PDAC
patients
66 14 male/16
female
Pancreatic ductal
adenocarcinoma
10.3 807 323 (40)
blasts of the different Th22/Tc22 Tcc subsets and stimulated with
100 ng/ml anti-CD3 mAb. On day 7, supernatants from each cell
culture were collected and evaluated by ELISA for IgM, IgG,
IgA and IgE content.
Flow cytometric detection of granzyme A and
evaluation of cell cytotoxicity
Granzyme A expression by Tcc was assessed according to the
manufacturer’s instructions (BD Biosciences). The different sub-
populations of IL-22-producing Tcc were tested for their ability
to kill P815 target cells upon anti-CD3 mAb activation (5 μg/ml)
by evaluating the percentage of annexin V-binding cells using
flow cytometry. The evaluation of apoptosis in Tcc and in L3.6pl
tumour cells was performed using the Annexin V kit (BD Bios-
ciences) following the manufacturer’s instructions. Cells were
then analysed on a FACSCanto cytofluorimeter (BDBiosciences)
using FACSDiva software.
Tumour cell cultures and in vitro cytotoxicity assay
Human PDACL3.6pl cells (cell line kindly provided by Professor
Paola Nistico`, Regina Elena National Cancer Institute, Rome,
Italy) were cultured in DMEM (Dulbecco’s modified Eagle’s
medium) (Lonza) supplemented with 10% (v/v) FBS (Lonza),
L-glutamine (GE Healthcare) and 50 μg/ml gentamicin (Genta-
lyn 40 mg/ml, Essex Italia) at 37 ◦C in a 5% CO2 atmosphere.
For the cytotoxicity assay, cells were seeded in 96-well plates at a
density of 2×104 cells per well, incubated for 4 h and then starved
overnight at 37 ◦C. Cells were treated with 100 ng/ml IL-22 or
IFNγ , or both, and incubated for 72 h; cell viability was then
determined using the MTT assay (Sigma). Briefly, 20 μl/well of
5 mg/ml MTT solution in PBS was added and incubated for 4 h
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at 37 ◦C. Medium was removed and 100 μl of DMSO was added
to each well. The formazan salts were quantified by reading the
absorbance at a test wavelength of 570 nm.
Immunohistochemical analysis
The surgical specimens of PDAC tissue were fixed in 4% para-
formaldehyde overnight at 4 ◦C, paraffin-embedded and cut using
a rotary microtome (MR2, Boeckeler Instruments). For immun-
ohistochemical staining, 5-μm sections of the blocks were in-
cubated overnight with rabbit anti-human PD-1 (programmed
cell death 1) mAb (clone EPR4877, 1:500 dilution; Abcam) or
mouse anti-humanFoxP3 (forkhead boxP3)mAbantibody (clone
22510, 5 μg/ml, 1:200 dilution; Abcam);mouse anti-humanCD4
mAb (neat, clone 4B12; Nichirei); mouse-anti-human CD8 mAb
(1:20 dilution, Dako Japan) or mouse anti-human CD163 an-
tibody (1:100 dilution, Leica Biosystems). Following antibody
incubation, samples were incubated at room temperature for
1 h with anti-rabbit or anti-mouse immunoglobulins conjugated
to a horseradish peroxidase-labelled dextran polymer (Simple
Staining Kit; Nichirei). After a benzidine reaction, sections were
lightly counterstained with haematoxylin.
For analysing the IL-22+ T-cells, sections were boiled for
10 min in sodium citrate buffer (10 mM, pH 6.0; Bio-Optica)
for antigen retrieval, and incubated in 2 mg/ml glycine (App-
liChem) for 10 min, to quench autofluorescence of the elastic
fibres. Non-specific binding was blocked by exposure to 1.5%
BSA in PBS for 20 min at room temperature. Sections were
immunolabelled overnight at 4 ◦C with mouse anti-CD3 mAb
(ready to use; GeneTex) and goat polyclonal anti-IL-22
mAb (1:50 dilution; Abcam). Immunoreactions were visual-
ized by incubation with specific anti-mouse and anti-goat Alexa
Fluor® 488- or 568-conjugated IgG (1:300 dilution; Molecular
Probes) for 2 h at room temperature. Negative controls were car-
ried out by replacing the primary antibodies with non-immune
serum. Digital images were obtained using an epifluorescence
Zeiss Axioskop microscope equipped with a ×63 oil-immersion
objective.
Staining of peripheral Th22 cells
PBMCs were isolated by density gradient centrifugation from
heparinized venous blood of PDAC patients or healthy sub-
jects. PBMC samples were characterized for their expression
of IL-22, IL-17 and IFN-γ using intracellular cytokine stain-
ing, as described previously [23]. Briefly, fresh or thawed PB-
MCs were cultured in IMDM (Iscove’s modified Dulbecco’s me-
dium) (BioWhittaker) supplemented with 10% FBS (Invitrogen)
and stimulated for 5 h with PMA (50 ng/ml) and ionomycin
(500 ng/ml) in the presence of BFA (brefeldin A) (10 μg/ml)
(all from Sigma–Aldrich). Cells were first stained for the surface
antigens CD4 (BD Biosciences), then fixed with 4% (w/v) para-
formaldehyde and permeabilizedwith 0.5% saponin, followed by
intracellular staining with anti-IL-22, anti-IL-17 and anti-IFN-γ
mAbs (BD Biosciences).
Statistical analysis
Results are expressed as the median (range) or the mean (+−S.D.).
Comparisons between the two groups were assessed using Stu-
dent’s t test. Correlations between the parameters were assessed
using Pearson’s correlation analysis. SPSS statistical software
(version 13.0) was used for all statistical analyses.
RESULTS
Isolation of IL-22-producing T-cells from PDAC
tissue
To evaluate the intra-tumoral subsets of IL-22-producing (IL-
22+) T-cells in PDAC patients, we expanded and cloned in vivo-
activated TILs isolated from two different sites, namely tumour
and surrounding healthy pancreas. We isolated Tcc from each
patient, and overall we obtained 807 Tcc; of these Tcc, 507 were
isolated from the cancer, which was almost double the number
of the Tcc isolated from the healthy pancreas (300) (Table 1).
Evaluating the surface markers of Tcc, we noticed that 710
(out of 807) (88%) were positive for CD4 and the remaining
97 were positive for CD8 (12%). After mitogen stimulation,
we assessed the levels of IL-22 secreted by single Tcc. We ob-
served that 323 Tcc (40%) were able to produce IL-22 and, more
precisely, 290 CD4+ and 33 CD8+ (Figure 1A). Of particular
interest, the number of Th22 cells increased at the cancer site;
we isolated 215 (74%) Th22 Tcc from the tumour and only 75
(26%) from the healthy mucosa. In addition, we registered sim-
ilar data on the CD8+ population, isolating 25 out of 33 (76%)
from the neoplastic tissue and only 8 (24%) from the surround-
ing healthy pancreatic tissue. Subsequently, we evaluated the
IL-22 levels secreted by the Tcc, and we found that the IL-22-
producing Tcc (both CD4+ and CD8+) isolated from the tu-
mour tissue significantly (P< 0.0001) produced higher levels of
IL-22 comparedwith the Tcc generated from the healthy pancreas
(Figure 1B).
Characterization of the cytokine profile of
IL-22-producing Tcc
As different T-cell subsets are able to produce IL-22, we also
evaluated which of the 323 IL-22-producing Tcc also produced
other cytokines.We observed that 61 (21%) out of 290 CD4+ Tcc
only secreted IL-22 (pure Th22), whereas 12 (4%) co-secreted
IL-4 (Th22/Th2), nine (3%) co-secreted IL-17 (Th22/Th17) and
44% (128/290) of the IL-22-producing Tcc were able to co-
secrete IFN-γ (Th22/Th1). The remaining 80 (28%) CD4+ Tcc
co-produced IFN-γ and IL-17 (Th22/Th1/Th17) (Figure 2A).
Out of the 33 IL-22+ CD8+ Tcc, we found that 19 (58%) Tcc co-
produced IFN-γ (Tc22/Tc1), four (11%) synthesized both IFN-γ
and IL-17 (Tc22/Tc1/Tc17) and five (15%) also produced IL-4
(Tc22/Tc2). The final five CD8+ Tcc (16%) were only able to
secrete IL-22 (Tc22) (Figure 2A).
The IL-22-producing Tcc subsets exhibit different
functional properties
To define the functional properties of IL-22-producing Tcc, we
then evaluated their ability to assist antibody production by
B-cells and to display cytotoxic activity, which we then com-
pared between the different IL-22+ Tcc. Both Th22/Th2 and
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Figure 1 Repertoire and IL-22 production of Tcc obtained from PDAC patients
(A) Total numbers of IL-22+ Tcc isolated from tumour tissue and the ratio of CD4+/CD8+ populations. The number of both
CD4+ and CD8+ IL-22+ Tcc is higher in the cancer site. (B) Evaluation and comparison of the amount of IL-22 secreted,
after mitogen stimulation, by the Tcc isolated from tumour tissue or surrounding healthy mucosa. The quantity of IL-22
produced by the Tcc (both CD4+ and CD8+) of tumour tissue is significantly (P< 0.0001) higher than that of Th22 cells
isolated from healthy mucosa.
Figure 2 Cytokine profile and functional profile of intra-tumoral Th22 isolated from PDAC patients
(A) Distribution of Th22 subsets. The major representative Tcc subtype is the Th22 with Th1 profile, for both the CD4+
population (white column) and the CD8+ population (black column). The percentage of Tcc producing only IL-22 (by our
definition, pure Th22) is 21 of CD4+ Th22 and 16 of CD8+ Tc22. (B) To assess the B-cell helper activity, we used
autologous B-cells co-cultured with 105 blasts of the different Th22/Tc22 Tcc subsets, stimulated with anti-CD3 antibody.
The supernatant content of different Ig subclasses was evaluated by commercial ELISA. (C) The granzyme A expression and
the percentage of annexin V-binding cells (D) were assessed according to the manufacturer’s instructions (BD Biosciences)
and analysed on a FACSCanto cytofluorimeter (BD Biosciences) using FACSDiva software.
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Figure 3 IL-22 reduced IFN-γ -induced apoptosis in the L3.6pl pancreatic tumour cell line
(A) Surface expression of IL-22R on L3.6pl cells after incubation with anti-IL-22R mAb (open curve) or isotype control (closed
curve). L3.6pl cells were treated with IL-22 (100 ng/ml), IFN-γ (100 ng/ml) or both for 72 h to evaluate cell viability (B)
or apoptotic cells (C). Cell viability was determined using the MTT assay and results are mean+−S.E.M. attenuances
(‘O.D.’) at 450 nm. Apoptotic cells were evaluated as the percentage of annexin V-positive cells. *P< 0.05; **P< 0.01;
***P< 0.001 (one-way ANOVA).
Th22/Th1 Tcc showed the ability to induce a major B-cell pro-
duction of IgM compared with the other subsets of IL22+ Tcc,
whereas the primary inducer of IgGwere theTh22/Th1Tcc.None
of the IL-22+ subsets was able to induce IgE production, whereas
all IL-22-producing Th subsets induced similar amounts of IgA
(Figure 2B).
Regarding the cytotoxic potential, all of the different IL22+
subsets exhibited low levels of granzyme A expression, as ex-
pected, with only the Th22/Th1 and Tc22/Tc1 Tcc displaying
granzyme A expression of approximately 20% or slightly more
(Figure 2C). We found analogous results regarding the ability
to induce apoptosis; all of the IL-22-producing Tcc displayed a
low percentage of annexin V-binding cells (<5%). Only the Tcc
(as CD4+ or CD8+) with a Th22/Th1 profile displayed a higher
percentage (Figure 2D).
IL-22 reduced IFN-γ -induced apoptosis in
pancreatic cells
As the majority of TILs produce IL-22 in combination with IFN-
γ , we evaluated the effect of IL-22 alone or in the presence of
IFN-γ on the human pancreatic tumour cell line L3.6pl, which
is a highly metastatic tumour cell line [32], the cells of which
express IL-22 receptor on their membrane (Figure 3A). IL-22
alone increases the cell viability of L3.6pl cells (Figure 3B); as
expected, IFN-γ treatment reduced cell viability (Figure 3B) and
induced strong apoptosis (Figure 3C) of L3.6pl cells. Interest-
ingly, these cytotoxic effects of IFN-γ were significantly reduced
by the presence of IL-22 (Figures 3B and 3C).
Immunohistochemical evaluation of intra-tumoral
IL-22+ T-cells
To verify whether the results obtained by the ex vivo model re-
flected a real situation, the presence of CD3+IL-22+ cells infilt-
rating PDAC tissues was evaluated using immunohistochemistry.
Among the infiltrating CD3+ T-cells (Figure 4A), CD4+ T-cells
were predominant compared with the CD8+ T-cells (results not
shown). Figures 4(B) and 4(C) only show representative images of
the T- (CD4+/CD8+) cell infiltration. FoxP3+ cells (Figure 4E), as
well as PD-1+ cells (Figure 4F), were more frequently observed,
suggesting that regulatory or activated CD4+ T-cells had infilt-
rated the PDAC tissues. Finally, we documented that the number
of CD3+ T-cells co-expressing IL-22 (Figure 4I) was higher in
the neoplastic tissue. Table 2 shows the number of inflammat-
ory cells which we assessed per high power field. Comparing
the PDAC tissue with the surrounding healthy mucosa, we noted
an increased number of CD4+, FoxP3+, PD-1+ and, especially,
IL-22+ T-cells in the tumour tissue. Finally, we also documented
that the number of IL-22-producing Tcc, isolated in a single pa-
tient, significantly correlated (P= 0.0076) with the number of
tumour-infiltrating IL-22+ cells, thus creating an important link
between the in vitro and in vivo data.
Th22 cells increase in the peripheral blood of PDAC
patients
Finally, the frequency of Th22 cells was assessed in the peri-
pheral blood of PDAC patients and 30 healthy subjects by flow
cytometry. After gating CD4+ cells, we identified three different
groups of IL-22-producing cells, namely one group producing
IL-22 alone (termed Th22 cells), one co-producing IFN-γ and
the last co-producing IL-17. The percentage of Th22 cells in
the peripheral blood of PDAC patients was significantly higher
than in age-matched healthy donors (Figure 5A). The expansion
of Th22 cells was accompanied by the increase of IL-22/IFN-
γ -co-producing (Figure 5B) and IL-22/IL-17-co-producing
(Figure 5C) CD4+ T-cells. However, the Th22 cell subset was
the highest IL-22-producing group in the peripheral blood.
Clinical relevance of Th22 cells in PDAC patients
The statistical analysis showed that IL-22-producing Tcc posit-
ively correlated with TNM staging (Figure 6A) and metastases
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Figure 4 Immunohistochemical analysis of PDAC tissues
Surgically resected PDAC tissues were immunohistochemically stained. CD3 (A): lymphoid aggregation around PDAC was
mainly composed of CD3+ T-cells. CD4 (B): the majority of lymphoid aggregation was CD4+ T-cells. CD8 (C): the number
of CD8+ T-cells was small compared with that of CD4+ T-cells shown in (B). Most T-cells were IL-22-positive (D), some
were FoxP3-positive (E) (nuclear expression) and some were PD-1-positive (F). Magnification ×10 high power field. In the
lower panels are digital images, obtained using an epifluorescence Zeiss Axioskop microscope equipped with a ×63
oil-immersion objective, of CD3+ T-cells (G), IL-22+ cells (H) and CD3+ IL-22+ T-cells (I). The images are from tissue of
different patients and are representative images of high/low-expressing samples for each marker.
(Figure 6B), but were not related to the sex or tumour size
(results not shown). Taken together, these results suggest that
IL-22 expression by T-cells is closely associated with PDAC pro-
gression and with the patient outcome. To test this hypothesis, we
evaluated whether the number of Th22 Tcc negatively correlated
with the survival of PDACpatients. The patientswere divided into
two groups on the basis of the percentage of intra-tumoral IL-22-
producing Tcc, either (i) <50% or (ii)50% (Table 1). Kaplan–
Meier analysis revealed that the patients of group (i) showed a
better survival comparedwith group (ii) (P< 0.0001), suggesting
a negative correlation between the percentage of IL-22-secreting
Tcc and a better outcome of the disease (Figure 6C). In other
words, elevated expression of intra-tumoral Th22 correlates with
PDAC progression and is a predictor of poor patient survival.
DISCUSSION
IL-22 is a member of the IL-10 family of cytokines produced by
T-cells and innate lymphoid cells [33]. The distribution of the two
IL-22 receptors, IL-22R1 and IL-10R2, indicates that the most
important target cells of IL-22 reside in the skin, digestive sys-
tem (pancreas and liver), lungs, and kidney. In general, the IL-22
signalling pathway orchestrates mucosal immune responses and
tissue regeneration through pleiotropic effects, including pro-
survival signalling, cell migration, dysplasia and angiogenesis
[34]. Although these functions can prevent the initial establish-
ment of tumours, they can also be exploited by aggressive can-
cers to enhance tumour growth and metastasis. In fact, as well as
being implicated in the pathogenesis of many autoimmune and
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Table 2 Inflammatory features of PDAC tissue and surrounding healthy pancreas
The number of each inflammatory cells was assessed per high power field.
Patient
Degree of
inflammation
CD4 tumour/healthy
mucosa
FoxP3 tumour/healthy
mucosa
PD-1 tumour/healthy
mucosa
IL-22 tumour/healthy
mucosa
01.PDAp Mild >100/>100 <10/<10 <5/<5 38/27
02.PDAp Moderate 54/62 58/22 14/6 45/31
03.PDAp Severe 83/80 <10/<10 41/27 62/48
04.PDAp Severe >100/>100 24/<10 10/<5 73/49
05.PDAp Severe 99/62 32 55/33 77/59
06.PDAp Severe 88/72 <10/<10 <5/<5 65/51
07.PDAp Mild >100/>100 37/20 <5/<5 18/8
08.PDAp Severe 98/82 25/15 44/25 63/48
09.PDAp Mild >100/>100 15/<10 21/8 72/54
10.PDAp Severe 80/63 <10/<10 12/<5 61/53
11.PDAp Moderate >100/>100 22/10 8/<5 61/49
12.PDAp Mild 71/82 13/<10 12/<5 38/29
13.PDAp Severe >100/82 22/15 15/6 70/56
14.PDAp Mild 52/72 48/34 <5/<5 55/46
15.PDAp Moderate >100/>100 28/17 19/8 47/38
16.PDAp Mild 63/75 11/<10 22/15 22/15
17.PDAp Moderate >100/>100 32/20 38/24 45/36
18.PDAp Severe 88/63 <10/<10 <5/<5 65/54
19.PDAp Severe 99/74 18/11 16/6 79/57
20.PDAp Mild >100/>100 35/21 13/<5 68/51
21.PDAp Severe >100/>100 <10/<10 25/16 72/49
22.PDAp Moderate >100/>100 28/21 14/8 76/51
23.PDAp Severe 88/>100 22/12 15/7 67/53
24.PDAp Mild 72/85 12/<10 <5/<5 54/42
25.PDAp Moderate >100/>100 <10/<10 31/20 19/8
26.PDAp Moderate 84/>100 18/<10 28/16 23/15
27.PDAp Moderate >100/>100 27/18 12/7 75/52
28.PDAp Severe >100/>100 <10/<10 <5/<5 78/49
29.PDAp Mild >100/>100 <10/<10 18/6 49/31
30.PDAp Moderate 68/78 14/<10 23/10 71/59
Figure 5 IL-22-producing cells in the peripheral blood of PDAC
Ex vivo FACS analysis of cytokine production from CD4+ T-cells in healthy subjects (HS) and in PDAC patients stimulated
for 5 h with PMA and ionomycin in the presence of BFA. Results are the percentages of IL-22-producing CD4+ cells in the
peripheral blood. *P< 0.001.
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Figure 6 Correlation between clinical parameters of patients and number of Th22 Tcc
Correlation between the percentages of Th22 cells with TNM stage (A) and presence of metastases (B). The increased
number of IL-22+ TILs positively and significantly correlates with TNM PDAC staging and number of metastases: −, no
metastases, +, metastases in one site, ++, multisite metastases. (C) To correlate the survival of PDAC patients with the
number of Th22 Tcc, we divided the patients into two groups: (i) patients with Th22 Tcc (50 %), and (ii) the patients with
Th22 Tcc (<50 %). Correlating the two groups by the Kaplan–Meier curve, we observed that group (ii) showed significantly
(P< 0.0001) better survival compared with group (i).
inflammatory diseases, such as psoriasis [35] and rheumatoid
arthritis [22], IL-22 has been associated with cancer progression,
including hepatocellular carcinoma [36] and gastric cancer [24].
However, the potential role of IL-22 and especially Th22 (the
major source of IL-22) in PDAC is far from clear.
In line with immunohistochemical analysis, which revealed
the presence ofCD3+IL-22+ cells in neoplastic tissue,we demon-
strated that the number of IL-22-producing CD4+ and CD8+ Tcc
isolated from PDAC patients was significantly elevated in PDAC
tissues compared with the surrounding healthy pancreas and, of
note, that the number of IL-22-producing Tcc significantly cor-
related with the number of tumour-infiltrating IL-22+ T-cells. In
other words, the number of IL-22+ Tcc reflects the in vivo situ-
ation. In addition, we demonstrated, for the first time, that the
IL-22-producing Tcc (as CD4+ or CD8+) isolated from PDAC
tissue significantly produced higher IL-22 levels compared with
IL-22+ Tcc isolated from the healthy pancreas. This finding sug-
gests that the high number of IL-22-producing T-cells can be
associated with PDAC progression and, in accordance with other
studies [28,29], Th22Tcc positively correlatedwith TNMstaging
and metastases. IL-22 improves the invasive ability of pancreatic
cancer cell lines by increasing MMP9 (matrix metalloproteinase
9), and the association between IL-22 and poor prognosis is at-
tributable to the increased cancer cell mobility and metastatic
potential [29].
IL-22 can be produced by different T-cell subpopulations,
in particular by the CD4+ T-cells: Th22, Th17 and Th1 [37].
Therefore, in order to evaluate the nature of the different IL-
22-producing Tcc that have infiltrated the neoplastic tissue, we
characterized the cytokine profile of each single IL-22-producing
Tcc. We observed that some CD4+ Tcc only produced IL-22, but
the majority of them co-produced IFN-γ alone or with IL-17,
and similarly only five out of the 33 CD8+ Tcc, secreted IL-
22 alone, whereas many co-produced IFN-γ or both IFN-γ and
IL-17. In conclusion, we have shown, for the first time, that in
PDAC patients, the major intra-tumoral source of IL-22 is the
T-cell subset with a Th1 profile.
Notably, as further confirmation of these ex vivo data, we also
documented a similar trend in vivo; in detail, we showed that
expansion of Th22 cells in the peripheral blood of PDAC patients
was accompanied by an increase in IL-22/IFN-γ -co-producing
and IL-22/IL-17-co-producing CD4+ T-cells.
Asmost of the IFN-γ -producingTcc are able to exert perforin-
mediated cytotoxicity, we assessed the cytolytic potential of IL-
22+ Tcc and, as expected, only the Th22/Th1 Tcc showed a
satisfactory expression of granzyme A, whereas the remaining
different IL-22-producing Tcc subsets exhibited low levels of
granzyme A. In addition, we registered analogous data about the
ability to induce apoptosis: of all IL-22+ Tcc, only those co-
producing IFN-γ (Th22/Th1) displayed a significant percentage
of annexin V-binding cells.
Indeed, as we have shown that PDAC cells express IL-22R,
they are responsible for the anti-apoptotic effect of IL-22. We
have shown that IFN-γ induced the apoptosis of PDAC cells and
that this apoptosis was antagonized by the addition of IL-22.
Taken together, these data support the hypothesis that IL-22
favours PDAC progression by inhibiting IFN-γ -induced apop-
tosis. The Il-22 production by intra-tumoral Th1/Th22 cells dur-
ing PDAC progression may therefore neutralize the anti-tumour
effect of Th1-polarized T-cells, protecting the cancer cells by the
pro-apoptotic effect of IFN-γ [38].
Finally, to complete the functional characterization of
intra-tumoral IL-22+ Tcc, we evaluated their ability to assist
antibody production by B-cells. In agreement with previous
studies [8], all of the different Th22 subsets of Tcc were un-
able to induce assistance for the production of IgE, but had
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a similar ability to induce IgA. In addition, both Th22/Th2
and Th22/Th1 Tcc induced IgM production, whereas only the
Th22 with a Th1 profile displayed an ability to induce IgG. In
other words, IL-22 does not seem to affect the isotype switch of
antibodies.
In summary, our results highlight the well-established dual
role of the anti-tumour immune response in PDAC patients. In-
deed, Th1 lymphocytes usually play an effector role against tu-
mour cells by assaulting them and then blocking tumour growth
[31,39,40]. Instead, in this context, the same Th1 cells, which
produce IL-22, could promote tumour progression, as demon-
strated recently in the pathogenesis of arthritis [41]. It is well
known that the pro-survival and proliferative effects of IL-22 are
utilized by many cancers; in particular, lung and liver cancers
appear to be particularly sensitive to these effects [36,42,43].
In addition, IL-22 can promote carcinogenesis by favouring an-
giogenesis [44,45] or enhancing immune evasion by tumours
[45]. PDAC cells themselves secrete VEGF (vascular endothelial
growth factor) and TGF-β (transforming growth factor β) and
IL-10 in response to IL-22 stimulation [45].
Finally, most importantly, our findings also shed light on the
clinical relevance of Th22 cells in PDAC. We found that an
increased frequency of Th22 cells correlated with TNM staging
andwith an unfavourable outcome of the disease, thus the number
of IL-22-producing Tcc negatively correlated with PDAC patient
survival.
Pancreatic cancer has a dismal 5-year survival rate of <5%,
partly because most patients are diagnosed when the disease
is already at an advanced stage, and partly because only 20%
of patients have local resectable tumours [46,47]. Increased re-
sponsiveness to IL-22 may be the tipping point which separates
resectable tumours from incurable and metastasized cancers (of-
ten already present at diagnosis). One study showed that the
expression of both IL-22 and IL-22R1 was elevated in sections
of PDAC tissue and predicted poorer patient survival [29]. How-
ever, a different group found that IL-22R1 was more poorly ex-
pressed in patients with PDAC compared with normal controls
[48]. Primary cells and metastases of oral squamous cell carcino-
mas showed intense staining for IL-22Rα1 [49]. Nonetheless, a
chromosomal loss of the region IL-22Rα1 was also found in a
cohort of Sudanese patients, but not in Norwegian patients of the
same study [50], mirroring the discrepancy between the results
in immunohistochemical observation and array comprehensive
genomic hybridization for pancreatic cancer. These data reveal
how differences in genotypes between ethnic groups may affect
the significance of IL-22 in a given cancer. IL-22R1 may also
be more affected specifically in buccal oral squamous cell car-
cinoma, which the majority of Sudanese patients had, but was
absent from the Norwegian cohort.
In conclusion, our data demonstrate that all IL-22-producing
T-cells are significantly increased in pancreatic cancer. Further-
more, these increases positively correlated with TNM staging of
PDAC and poorer patient survival. These novel findings suggest
that Th22 cells may participate in PDAC pathogenesis, that the
monitoring of Th22 can be a good diagnostic parameter and, fi-
nally, that blockade of IL-22 signalling may represent a viable
method for anti-PDAC therapies.
CLINICAL PERSPECTIVES
• The principal sources of IL-22 are Th22 cells, which secrete
only IL-22 or other cytokines such as IL-17 or IFN-γ . Intra-
tumoral IL-22 levels were elevated in PDAC (pancreatic ductal
adenocarcinoma). However, the nature, role and clinical rel-
evance of Th22 remain unknown.
• We have shown that in PDAC patients, cytotoxic IFN-γ+
Th22 cells are the major intra-tumoral source of IL-22, which
induce apoptosis, and are antagonized by IL-22. The increased
levels of Th22 positively correlated with TNM and poorer
patient survival.
• Elucidation of how IL-22 regulates the pathogenesis of PDAC
is important, and may help to identify a new target for devel-
oping innovative PDAC treatments.
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